



Kidney Cancer Research Summit **KCRS21**

*Join us as we collaborate,
share innovations, and discuss
research progress.*

October 7 – 8, 2021

Philadelphia • PA



Kidney CAN

Accelerating Cures


kidneycan.org



We hope you will join us at Estia

October 7, 6:00pm

1405-07 Locust Street
Philadelphia, PA 19102



Contents

| | |
|---|------------|
| Opening Session: Fireside Chat with Gordon Freeman & Arlene Sharpe | 4 |
| Welcome | 5 |
| KCRS21 Faculty | 6-7 |
| Program – October 7 | 8-9 |
| Program – October 8 | 10-11, 13 |
| KCRS21 Speakers | 14-15 |
| Save the Date | Back cover |



11:10am-12:00pm
Thursday, October 7, 2021



Photo by Sam Ogden / Dana-Farber

Fireside Chat with Gordon Freeman and Arlene Sharpe

OUR LIVES WITH IMMUNOLOGY

Join us for our opening session featuring Gordon Freeman and Arlene Sharpe as they discuss their groundbreaking work in the pathways that inhibit T cell activation. In addition to discussing their science and careers, we'll be asking about their commitment to mentorship and managing family life as researchers.

Questions from the live and virtual audience will follow.

Get Involved!

Ask questions during the sessions

Join us at

slido.com

using **#016267**



Welcome

On behalf of the Executive Steering Committee, we welcome you to the beautiful and historic city of Philadelphia for the 2021 Kidney Cancer Research Summit (KCRS21).

This year marks our third annual meeting, and despite challenges presented by the Covid-19 pandemic, we are proud to say that the program we have planned is more exciting than ever. In the two days ahead, you will have the opportunity to hear from the world's leading kidney cancer researchers as they celebrate groundbreaking accomplishments and explore innovative directions in kidney cancer treatment.

The mission of KidneyCAN is to accelerate cures for kidney cancer. KCRS brings together the very people who are pursuing these cures and provides you with opportunities for stimulating discussion and collaboration.

With over 400,000 people per year diagnosed globally, and more than 131,000 of those people losing their lives, there is an urgency to our work that cannot be overstated. Your attendance here signifies a commitment to our shared cause, and we thank you for being a part of the Kidney Cancer Research Summit (KCRS21).

We look forward to a dynamic meeting and great conversations!

Sincerely,

TONI CHOUERI, M.D.
Dana-Farber Cancer Institute
Director, Lank Center for
Genitourinary Oncology

HANS HAMMERS, M.D., Ph.D
UT Southwestern Medical Center
Associate Professor of Internal Medicine,
Division of Hematology-Oncology

BRYAN LEWIS
President
KidneyCAN

SUSAN POTEAT
Medical Science Liaison
KidneyCAN

With thanks to our sustaining partners



Executive Steering Committee

TONI CHOEIRI, M.D.
Dana-Farber Cancer Institute
 Director, Lank Center for Genitourinary
 Oncology

HANS HAMMERS, M.D., Ph.D.
UT Southwestern Medical Center
 Associate Professor of Internal Medicine,
 Division of Hematology-Oncology

BRYAN LEWIS
KidneyCAN
 President

SUSAN POTEAT
KidneyCAN
 Medical Science Liaison

Communications Committee

NEERAJ AGARWAL, M.D.
Huntsman Cancer Institute
 Senior Director of Clinical Research Innovation

GIL MORGAN, M.D.
Skane University Hospital
 Medical Oncologist

FABIO SCHUTZ, M.D.
BP – A Beneficencia,
Portuguesa de Sao Paulo
 Oncologista Clinico

QING ZHANG, Ph.D.
UT Southwestern
 Associate Professor of Pathology

TIAN ZHANG, M.D.
Duke Cancer Institute
 Associate Professor of Medicine

ADRIAN HAYES
KidneyCAN
 Communications Consultant

Original Abstract/Research Committee

LAURENCE ALBIGES, M.D., Ph.D
Institut Gustave-Roussy
 Urology Committee Chairman

ARI HAKIMI, M.D.
Memorial Sloan Kettering Cancer Center
 Assistant Attending, Department of Surgery

RANA MCKAY, M.D.
University of California, San Diego
 Associate Professor of Medicine

PAVLOS MSAOUEL, M.D., Ph.D.
MD Anderson Cancer Center
 Assistant Professor of GU Oncology

SUMANTA PAL, M.D.
City of Hope Comprehensive Cancer Center
 Associate Clinical Professor, Department of
 Medical Oncology & Therapeutics Research

QING ZHANG, Ph.D.
UT Southwestern Medical Center
 Associate Professor, Department of Pathology

Moderators

MICHAEL ATKINS, M.D.
**Georgetown Lombardi Comprehensive
 Cancer Center**
 Deputy Director

TONI CHOEIRI, M.D.
Dana-Farber Cancer Institute
 Director, Lank Center for Genitourinary
 Oncology

ARI HAKIMI, M.D.
Memorial Sloan Kettering Cancer Center
 Assistant Attending, Department of Surgery

HANS HAMMERS, M.D., Ph.D.
UT Southwestern Medical Center
 Associate Professor of Internal Medicine,
 Division of Hematology-Oncology

ERIC JONASCH, M.D.
MD Anderson Cancer Center
 Professor, Dept. of Genitourinary Medical Oncology

RANA MCKAY, M.D.
University of California, San Diego
 Associate Professor of Medicine

MOSHE ORNSTEIN, M.D., M.A.
Cleveland Clinic
 Genitourinary Medical Oncologist

SUMANTA PAL, M.D.
City of Hope Comprehensive Cancer Center
 Associate Clinical Professor, Department of
 Medical Oncology & Therapeutics Research

BRIAN RINI, M.D.
Vanderbilt University Medical Center
 Chief of Medical Trials

SCOTT TYKODI, M.D., Ph.D.
University of Washington Medicine
 Associate Professor, Division of Medical Oncology

NIZAR TANNIR, M.D., FACP
MD Anderson Cancer Center
 Professor, Dept. of Genitourinary Medical Oncology

Programmatic Committee

ERIC JONASCH, M.D.
MD Anderson Cancer Center
 Professor, Department of Genitourinary
 Medical Oncology

KIMRYN RATHMELL, M.D., Ph.D.
Vanderbilt University Medical Center
 Director, Division of Hematology & Oncology

8:30am – 11:00am

Registration, Breakfast and Connections

11:00am – 12:00pm

Welcome and Introduction

Fireside Chat with Gordon Freeman and Arlene Sharpe

12:00 – 1:00pm

Tumor Evolution/Mechanisms of Lethality

Moderated by Scott Tykodi, UW Medicine & Eric Jonasch, MDACC

Targeting the Osteogenic Niche for Preventing Kidney Cancer Bone Metastasis Progression
Robert Satcher, MD Anderson Cancer Center

Epigenetic Modifications of Cytosines in Clear Cell Kidney Carcinogenesis and Survival
Lucas Salas, Dartmouth College

Analysis of Transcriptional Profiles During the Evolution of ccRCC from Premalignant to Malignant Lesions
Olivia Lombardi, University of Oxford

Dissecting the Periostin-Directed Metastatic Cross Talk in Clear Cell Renal Cell Carcinoma
Lily Wu, University of California, Los Angeles

Lunch

2:00 – 3:00pm

Innovative Non-immune Therapy Related Therapeutics and Monitoring

Moderated by Eric Jonasch, MDACC & Moshe Ornstein, Cleveland Clinic

The Investigation of Ferroptosis as a Novel Therapeutic Paradigm for Kidney Cancer
Mei Yee Koh, Kuda Therapeutics, Inc.

Exploiting Cholesterol Metabolism to Treat Primary and Metastatic Renal Carcinoma
Marie Simon, University of Pennsylvania

Innovative non-immune therapy related therapeutics and monitoring cont.

Monitoring Disease Burden and Biology Using Tumor Cell-Free DNA in Metastatic Kidney Cancer
Scott Haake, Vanderbilt University Medical Center

Exploiting Epigenetic Dysregulation to Identify Targetable Vulnerabilities in ccRCC
Abhishek Chakraborty, Cleveland Clinic Foundation

3:00 - 4:00pm

Non-Clear Cell RCC

Moderated by Nizar Tannir, MDACC & Ari Hakimi, MSKCC

Development of Mouse Models for Variant RCC Histologies
Giannicola Genovese, MD Anderson Cancer Center

Unlocking the Human Relevance of a New Genetic Papillary Renal Cell Carcinoma Mouse Model
Richard Link, Baylor College of Medicine

The Pathogenesis and Therapy of Chromophobe Renal Cell Carcinoma
Elizabeth Henske, Brigham and Women's Hospital

Genomic and Functional Analysis of Translocation Renal Cell Carcinoma
Srinivas Viswanathan, Dana-Farber Cancer Institute

A Novel Mechanism of Pathogenesis for Renal Medullary Carcinoma
Pavlos Msaouel, MD Anderson Cancer Center

4:00pm

Closing Remarks & Group Picture

The virtual event will be broadcast from Eastern Daylight Time (EDT) and begins at 11:00 a.m. on Thursday and 8:00 a.m. on Friday.

8:00 – 8:10am

Welcome and Introductions

8:10 – 9:30am

Immunotherapy Advances and Research

Moderated by Hans Hammers, UTSW & Michael Atkins, GLCCC

Immunotherapy Based Biomarkers that Could Relate or Inspire RCC Research

Janis Taube, Johns Hopkins University

Integrated Analysis of Somatic Genomic Mutations and Antigen Presentation as Predictive Biomarkers for Combination Immunotherapy in Kidney Cancer

Chung-Han Lee, Memorial Sloan Kettering Cancer Center

Understanding CD8+ T-Cell Specificity and Function in Renal Cell Carcinoma

David Braun, Dana-Farber Cancer Institute

Combining Locally Administered Ipilimumab with a Personalized Neoantigen Cancer Vaccine to Improve T-Cell Priming and Antitumor Immunity in High-Risk Renal Cell Carcinoma

Catherine Wu, Dana-Farber Cancer Institute

Overcoming Kidney Cancer Resistance to Immune Checkpoint Inhibitors

Kiyoshi Ariizumi, UT Southwestern Medical Center

9:45 – 10:45am

Clinical and Scientific Updates in Kidney Cancer

Moderated by Toni Choueiri, DFCI & Brian Rini, VUMC

Recent Clinical Trial Results

Elizabeth Plimack, Fox Chase Cancer Center

Translational Research Updates in Renal Cancer

Tom Powles, Barts Cancer Centre

First Line Therapy and New Agents

Robert Motzer, Memorial Sloan Kettering Cancer Center

11:15am – 12:15pm

Abstract Oral Presentations

Moderated by Sumanta Pal, CHCCC & Rana McKay, UC, San Diego

A phase 3 trial of lenvatinib plus pembrolizumab versus sunitinib as a first-line treatment for patients with advanced renal cell carcinoma: overall survival follow-up analysis (the CLEAR study)

Toni Choueiri, Dana-Farber Cancer Institute

Characterization of responders in the phase 3 CheckMate 9ER trial: nivolumab plus cabozantinib versus sunitinib in patients with previously untreated advanced renal cell carcinoma

Amishi Shah, MD Anderson Cancer Center

Pembrolizumab (pembro) vs placebo as post nephrectomy adjuvant therapy for patients with renal cell carcinoma (RCC): randomized, double-blind, phase 3 KEYNOTE-564 study

Toni Choueiri, Dana-Farber Cancer Institute

Nivolumab/ipilimumab with or without CBM588 in metastatic renal cell carcinoma: a randomized phase Ib study and in-depth analysis of gut microbiome evolution

Nazli Dizman, Yale New Haven Hospital

Integrative Clinical and Molecular Characterization of Translocation Renal Cell Carcinoma

Ziad Bakouny, Dana-Farber Cancer Institute

Generation of an in vivo CRISPR/Cas9-based ccRCC model using AAV

Laura Stransky, Dana-Farber Cancer Institute

1:15 – 2:15pm

Abstract Rapid Presentations

Moderated by Sumanta Pal, CHCCC & Rana McKay, UC, San Diego

Potential Role of Seleno-L-Methionine (SLM) in Stabilization of Tumor Vasculature and Enhanced Efficacy of Axitinib in Previously Treated Patients with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

Yousef Zakharia, University of Iowa



Abstract Rapid Presentations cont.

Real-world treatment patterns and outcomes of front-line axitinib plus pembrolizumab versus ipilimumab plus nivolumab for metastatic clear cell renal cell carcinoma

Kevin Zarrabi, Fox Chase Cancer Center

Characterizing the immune response in patients with renal cell carcinoma (RCC) following COVID-19 vaccination

Jasnoor Malhotra, City of Hope Comprehensive Cancer Center

Histologic Growth Patterns in Nephrectomy Specimens of Clear Cell Renal Cell Carcinoma Inform Tumor Evolution

Nicolas Sayegh, Huntsman Cancer Institute

Transcriptomic analysis predicts resistance and toxicity in metastatic renal cell carcinoma (mRCC) patients treated with immune checkpoint inhibitors (ICI)

Lucia Carril-Ajuria, University Hospital 12 de Octubre

Ultra-sensitive ctDNA distinguishes complete response (CR) and partial response (PR) with immunotherapy in metastatic renal cell carcinoma (mRCC) patients

Alex Chehrazi-Raffle, City of Hope Comprehensive Cancer Center

Seq-ing the source of radiation-induced anti-tumor immunogenicity in renal cell carcinoma patient tumors

Jason Muhitch, Roswell Park Comprehensive Cancer Center

Multiplex analysis of the tumor microenvironment (TME) in papillary renal cell carcinoma (pRCC) suggests a role of macrophages in therapeutic response

Nicholas Salgia, University at Buffalo

2:15 –2:30pm **KCRS Session Close**

KidneyCAN engages in patient advocacy and power research by supporting government and industry research funding, facilitating research collaborations, and offering direct financial support for clinical and laboratory researchers with promising ideas. Together, we can accelerate cures.

FOLLOW US ON SOCIAL MEDIA

@kidneyCAN



#KCRS21

Be sure to tag KidneyCAN and use the **#KCRS21** hashtag

KIYOSHI ARIIZUMI, Ph.D.
UT Southwestern Medical Center
 Professor

ZIAD BAKOUNY, M.D., MSc.
Dana-Farber Cancer Institute
 Internal Medicine Resident

DAVID BRAUN, M.D., Ph.D.
Dana-Farber Cancer Institute
 Fellow in Medical Oncology

LUCIA CARRIL-AJURIA, M.D.
University Hospital 12 de Octubre
 Medical Oncology Department

ABHISHEK CHAKRABORTY, Ph.D.
Cleveland Clinic Foundation
 Assistant Professor

ALEX CHEHRAZI-RAFFLE, M.D.
City of Hope Comprehensive Cancer Center
 Research Fellow

TONI CHOEIRI, M.D.
Dana-Farber Cancer Institute
 Director, Lank Center for Genitourinary Oncology

NAZLI DIZMAN, M.D.
Yale New Haven Hospital
 Internal Medicine Resident

GORDON FREEMAN, PH.D.
 Harvard Medical School
 Professor of Medicine

GIANNICOLA GENOVESE, M.D., Ph.D.
MD Anderson Cancer Center
 Assistant Professor

SCOTT HAAKE, M.D.
Vanderbilt University Medical Center
 Assistant Professor

ELIZABETH HENSKÉ, M.D.
Brigham and Women's Hospital
 Professor

MEI YEE KOH, Ph.D.
Kuda Therapeutics, Inc.
 Founder and CEO

CHUNG-HAN LEE, M.D., Ph.D.
Memorial Sloan Kettering Cancer Center
 Medical Oncologist

RICHARD LINK, M.D., Ph.D.
Baylor College of Medicine
 Professor of Urology

OLIVIA LOMBARDI, Ph.D.
University of Oxford
 Post Doctoral Researcher

JASNOOR MALHOTRA
City of Hope Comprehensive Cancer Center
 Clinical Research Associate

ROBERT MOTZER, M.D.
Memorial Sloan Kettering Cancer Center
 Jack and Dorothy Byrne Chair in Clinical Oncology

PAVLOS MSAOUEL, M.D., Ph.D.
MD Anderson Cancer Center
 Assistant Professor of GU Oncology

JASON MUHITCH, Ph.D.
Roswell Park Comprehensive Cancer Center
 Assistant Professor

ELIZABETH PLIMACK, M.D.
Fox Chase Cancer Center
 Chief, Division of Genitourinary Medical Oncology

TOM POWLES, MBBS, MRCP, M.D.
Barts Cancer Centre
 Director, Barts Cancer Centre,
 Lead for Solid Tumour Research

LUCAS SALAS, M.D., MPH, Ph.D.
Geisel School of Medicine at Dartmouth
 Assistant Professor

NICHOLAS SALGIA
University at Buffalo
 M.D.-PhD Student at the Jacobs School of Medicine
 and Biomedical Sciences

ROBERT SATCHER, M.D.
MD Anderson Cancer Center
 Associate Professor

NICOLAS SAYEGH, M.D.
Huntsman Cancer Institute
 Research Fellow

AMISHI SHAH, M.D.
MD Anderson Cancer Center
 Assistant Professor

ARLENE SHARPE, M.D., Ph.D.
Harvard Medical School
 Chair of the Department of Immunology

M. CELESTE SIMON, Ph.D.
University of Pennsylvania
 Arthur H. Rubenstein, MBBCh Professor

LAURA STRANSKY, Ph.D.
Dana-Farber Cancer Institute
 Research Fellow

JANIS TAUBE, M.D., MSc.
Johns Hopkins University
 Professor

SRINIVAS VISWANATHAN, M.D., Ph.D.
Dana-Farber Cancer Institute
 Assistant Professor of Medicine

CATHERINE WU, M.D.
Dana-Farber Cancer Institute
 Chief, Division of Stem Cell Transplantation and
 Cellular Therapies

LILY WU, M.D., Ph.D.
University of California, Los Angeles
 Professor

YOUSEF ZAKHARIA, M.D.
University of Iowa
 Clinical Associate Professor

KEVIN ZARRABI, M.D.
Fox Chase Cancer Center
 Research Fellow



Memories from KCRS 2019 & 2020

Save the Date!



KCRS22 October 6-7, 2022

“It’s one of the most exciting things I’ve ever participated in. We’re bringing together clinicians, physician scientists, and bench scientists to talk about kidney cancer research. The goal is to invigorate the science and spur breakthroughs.”

DR. HANS HAMMERS, UTSW

KidneyCAN
8327 Germantown Ave
Philadelphia, PA 19118
e: info@kidneycan.org
w: kidneycan.org



**Kidney Cancer
Research Summit** KCRS21